filings.toolsItem 1. Financial Statements
92K characters. Original on sec.gov · Markdown
Item 1. Financial Statements
IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In millions, except per share amounts)
(unaudited)
| Three Months Ended March 31, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| Net sales | $ | 886.9 | $ | 814.3 | |||||||||||||||||||
| Cost of sales | 488.8 | 445.4 | |||||||||||||||||||||
| Gross profit | 398.1 | 368.9 | |||||||||||||||||||||
| Selling, general and administrative expenses | 218.3 | 209.4 | |||||||||||||||||||||
| Restructuring expenses and asset impairments | 7.4 | 17.5 | |||||||||||||||||||||
| Operating income | 172.4 | 142.0 | |||||||||||||||||||||
| Other (income) expense – net | (0.6) | 1.4 | |||||||||||||||||||||
| Interest expense – net | 16.0 | 16.1 | |||||||||||||||||||||
| Income before income taxes | 157.0 | 124.5 | |||||||||||||||||||||
| Provision for income taxes | 37.1 | 29.1 | |||||||||||||||||||||
| Net income | 119.9 | 95.4 | |||||||||||||||||||||
| Net loss attributable to noncontrolling interest | 0.1 | 0.1 | |||||||||||||||||||||
| Net income attributable to IDEX | $ | 120.0 | $ | 95.5 | |||||||||||||||||||
| Earnings per common share: | |||||||||||||||||||||||
| Basic earnings per common share attributable to IDEX | $ | 1.61 | $ | 1.26 | |||||||||||||||||||
| Diluted earnings per common share attributable to IDEX | $ | 1.61 | $ | 1.26 | |||||||||||||||||||
| Share data: | |||||||||||||||||||||||
| Basic weighted average common shares outstanding | 74.3 | 75.7 | |||||||||||||||||||||
| Diluted weighted average common shares outstanding | 74.4 | 75.8 |
See Notes to Condensed Consolidated Financial Statements
IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In millions)
(unaudited)
| Three Months Ended March 31, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| Net income | $ | 119.9 | $ | 95.4 | |||||||||||||||||||
| Other comprehensive (loss) income: | |||||||||||||||||||||||
| Pension and other postretirement adjustments, net of tax | (0.2) | (0.2) | |||||||||||||||||||||
| Cumulative translation adjustment | (43.5) | 53.9 | |||||||||||||||||||||
| Other comprehensive (loss) income, net of tax | (43.7) | 53.7 | |||||||||||||||||||||
| Comprehensive income | 76.2 | 149.1 | |||||||||||||||||||||
| Comprehensive loss attributable to noncontrolling interest | 0.1 | 0.1 | |||||||||||||||||||||
| Comprehensive income attributable to IDEX | $ | 76.3 | $ | 149.2 |
See Notes to Condensed Consolidated Financial Statements
IDEX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In millions, except per share amounts)
(unaudited)
| March 31, 2026 | December 31, 2025 | ||||||||||
| ASSETS | |||||||||||
| Current assets | |||||||||||
| Cash and cash equivalents | $ | 586.2 | $ | 580.0 | |||||||
| Receivables – net | 553.0 | 521.7 | |||||||||
| Inventories – net | 501.0 | 479.4 | |||||||||
| Other current assets | 76.5 | 62.1 | |||||||||
| Total current assets | 1,716.7 | 1,643.2 | |||||||||
| Property, plant and equipment – net of accumulated depreciation of $670.6 and $653.4 at March 31, 2026 and December 31, 2025, respectively | 462.3 | 468.0 | |||||||||
| Goodwill | 3,390.2 | 3,414.5 | |||||||||
| Intangible assets – net | 1,200.2 | 1,247.4 | |||||||||
| Other noncurrent assets | 149.2 | 153.9 | |||||||||
| Total assets | $ | 6,918.6 | $ | 6,927.0 | |||||||
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities | |||||||||||
| Trade accounts payable | $ | 224.8 | $ | 224.7 | |||||||
| Accrued expenses | 280.6 | 297.0 | |||||||||
| Current portion of long-term borrowings | 0.5 | 0.7 | |||||||||
| Dividends payable | 0.1 | 53.0 | |||||||||
| Total current liabilities | 506.0 | 575.4 | |||||||||
| Long-term borrowings – net | 1,871.8 | 1,820.1 | |||||||||
| Deferred income taxes | 299.5 | 303.0 | |||||||||
| Other noncurrent liabilities | 192.9 | 202.3 | |||||||||
| Total liabilities | 2,870.2 | 2,900.8 | |||||||||
| Commitments and contingencies (Note 14) | |||||||||||
| Shareholders’ equity | |||||||||||
| Preferred stock: | |||||||||||
| Authorized: 5.0 million shares, $0.01 per share par value; Issued: None | — | — | |||||||||
| Common stock: | |||||||||||
| Authorized: 150.0 million shares, $0.01 per share par value | |||||||||||
| Issued: 90.1 million shares at both March 31, 2026 and December 31, 2025 | 0.9 | 0.9 | |||||||||
| Treasury stock at cost: 15.8 million shares at March 31, 2026 and 15.5 million shares at December 31, 2025 | (1,453.6) | (1,423.2) | |||||||||
| Additional paid-in capital | 868.5 | 892.1 | |||||||||
| Retained earnings | 4,620.1 | 4,500.1 | |||||||||
| Accumulated other comprehensive income | 13.9 | 57.6 | |||||||||
| Total shareholders’ equity | 4,049.8 | 4,027.5 | |||||||||
| Noncontrolling interest | (1.4) | (1.3) | |||||||||
| Total equity | 4,048.4 | 4,026.2 | |||||||||
| Total liabilities and equity | $ | 6,918.6 | $ | 6,927.0 |
See Notes to Condensed Consolidated Financial Statements
IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(In millions, except per share amounts)
(unaudited)
| Common Stock Shares | Common Stock and Additional Paid-In Capital | Treasury Stock Shares | Treasury Stock | Accumulated Other Comprehensive Income (Loss) | Retained Earnings | Total Shareholders’ Equity | Noncontrolling Interest | Total Equity | |||||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended March 31, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, December 31, 2025 | 90.1 | $ | 893.0 | 15.5 | $ | (1,423.2) | $ | 57.6 | $ | 4,500.1 | $ | 4,027.5 | $ | (1.3) | $ | 4,026.2 | |||||||||||||||||||||||||||||||||||||
| Net income (loss) | — | — | — | — | — | 120.0 | 120.0 | (0.1) | 119.9 | ||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive loss (net of tax of $—) | — | — | — | — | (43.7) | — | (43.7) | — | (43.7) | ||||||||||||||||||||||||||||||||||||||||||||
| Net issuance of shares of treasury stock (net of tax withholdings of $1.2) | — | (39.4) | (0.1) | 45.2 | — | — | 5.8 | — | 5.8 | ||||||||||||||||||||||||||||||||||||||||||||
| Repurchases of common stock (including excise tax of $0.6) | — | — | 0.4 | (75.6) | — | — | (75.6) | — | (75.6) | ||||||||||||||||||||||||||||||||||||||||||||
| Share-based compensation | — | 15.8 | — | — | — | — | 15.8 | — | 15.8 | ||||||||||||||||||||||||||||||||||||||||||||
| Balance, March 31, 2026 | 90.1 | $ | 869.4 | 15.8 | $ | (1,453.6) | $ | 13.9 | $ | 4,620.1 | $ | 4,049.8 | $ | (1.4) | $ | 4,048.4 | |||||||||||||||||||||||||||||||||||||
| Three Months Ended March 31, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, December 31, 2024 | 90.1 | $ | 865.7 | 14.2 | $ | (1,170.3) | $ | (130.9) | $ | 4,230.2 | $ | 3,794.7 | $ | (0.6) | $ | 3,794.1 | |||||||||||||||||||||||||||||||||||||
| Net income (loss) | — | — | — | — | — | 95.5 | 95.5 | (0.1) | 95.4 | ||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income (net of tax of $—) | — | — | — | — | 53.7 | — | 53.7 | — | 53.7 | ||||||||||||||||||||||||||||||||||||||||||||
| Net issuance of shares of treasury stock (net of tax withholdings of $2.7) | — | — | (0.1) | (0.5) | — | — | (0.5) | — | (0.5) | ||||||||||||||||||||||||||||||||||||||||||||
| Repurchases of common stock (including excise tax of $0.4) | — | — | 0.3 | (50.4) | — | — | (50.4) | (50.4) | |||||||||||||||||||||||||||||||||||||||||||||
| Share-based compensation | — | 13.6 | — | — | — | — | 13.6 | — | 13.6 | ||||||||||||||||||||||||||||||||||||||||||||
| Balance, March 31, 2025 | 90.1 | $ | 879.3 | 14.4 | $ | (1,221.2) | $ | (77.2) | $ | 4,325.7 | $ | 3,906.6 | $ | (0.7) | $ | 3,905.9 |
See Notes to Condensed Consolidated Financial Statements
IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(unaudited)
| Three Months Ended March 31, | |||||||||||
| 2026 | 2025 | ||||||||||
| Cash flows from operating activities | |||||||||||
| Net income | $ | 119.9 | $ | 95.4 | |||||||
| Adjustments to reconcile net income to net cash flows provided by operating activities: | |||||||||||
| Asset impairments | 4.8 | — | |||||||||
| Depreciation | 19.9 | 18.4 | |||||||||
| Amortization of intangible assets | 33.8 | 31.5 | |||||||||
| Share-based compensation expense | 15.8 | 13.6 | |||||||||
| Deferred income taxes | (0.6) | 0.9 | |||||||||
| Changes in (net of the effect from acquisitions/divestitures and foreign currency translation): | |||||||||||
| Receivables – net | (35.4) | (12.3) | |||||||||
| Inventories – net | (25.5) | (34.9) | |||||||||
| Other current assets | (15.1) | (7.0) | |||||||||
| Trade accounts payable | 0.6 | 9.6 | |||||||||
| Deferred revenue | 4.2 | 8.8 | |||||||||
| Accrued expenses | (18.8) | (17.9) | |||||||||
| Other – net | 0.1 | (0.4) | |||||||||
| Net cash flows provided by operating activities | 103.7 | 105.7 | |||||||||
| Cash flows from investing activities | |||||||||||
| Capital expenditures | (17.7) | (14.3) | |||||||||
| Acquisition of business, net of cash acquired | — | 4.2 | |||||||||
| Other – net | (2.7) | 0.1 | |||||||||
| Net cash flows used in investing activities | (20.4) | (10.0) | |||||||||
| Cash flows from financing activities | |||||||||||
| Borrowings under revolving credit facilities | 100.0 | — | |||||||||
| Payments under revolving credit facilities | (45.3) | (30.2) | |||||||||
| Cash dividends paid to shareholders | (52.8) | (52.4) | |||||||||
| Proceeds (payments) from share issuances, net of shares withheld for taxes | 5.8 | (0.5) | |||||||||
| Repurchases of common stock | (76.3) | (50.0) | |||||||||
| Other – net | (0.2) | (0.2) | |||||||||
| Net cash flows used in financing activities | (68.8) | (133.3) | |||||||||
| Effect of exchange rate changes on cash and cash equivalents | (8.6) | 10.9 | |||||||||
| Net increase (decrease) in cash and cash equivalents and restricted cash | 5.9 | (26.7) | |||||||||
| Cash and cash equivalents and restricted cash at beginning of year(1) | 585.9 | 638.9 | |||||||||
| Cash and cash equivalents and restricted cash at end of period(1) | $ | 591.8 | $ | 612.2 | |||||||
| Supplemental cash flow information | |||||||||||
| Cash paid for: | |||||||||||
| Interest | $ | 15.1 | $ | 15.6 | |||||||
| Income taxes – net | 19.7 | 19.8 |
(1) The Company has restricted cash related to certain letters of credit and is required to keep these balances in separate accounts for the duration of the letter of credit agreements. The underlying letters of credit expire between June 2026 and July 2027. The Company also has restricted cash related to funds held in escrow for the payment of certain merger consideration in connection with the acquisition of Micro-LAM, Inc. These payments are expected to be paid between July 2026 and January 2028. Restricted cash is included in the Condensed Consolidated Balance Sheets as follows:
| Restricted Cash | ||||||||||||||||||||||||||
| March 31, 2026 | December 31, 2025 | March 31, 2025 | December 31, 2024 | |||||||||||||||||||||||
| Other current assets | $ | 2.7 | $ | 3.0 | $ | 16.5 | $ | 18.1 | ||||||||||||||||||
| Other noncurrent assets | 2.9 | 2.9 | 1.6 | — | ||||||||||||||||||||||
| Total | $ | 5.6 | $ | 5.9 | $ | 18.1 | $ | 18.1 |
See Notes to Condensed Consolidated Financial Statements
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions, except per share amounts)
(unaudited)
1. Basis of Presentation and Significant Accounting Policies
The Condensed Consolidated Financial Statements of IDEX Corporation (“IDEX” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) applicable to interim financial information and the instructions to Form 10-Q under the Securities Exchange Act of 1934, as amended. The statements are unaudited but include all adjustments, consisting only of recurring items, except as noted, that the Company considers necessary for a fair presentation of the information set forth herein. The results of operations for the three months ended March 31, 2026 are not necessarily indicative of the results to be expected for the entire year.
The Condensed Consolidated Financial Statements set forth in this report should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
Recently Issued Accounting Standards
In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which requires public entities to disclose, within the footnotes to the financial statements, disaggregated information about certain income statement expense captions, including disclosure of amounts for purchases of inventory, employee compensation, depreciation and intangible asset amortization, included in each relevant expense caption. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Adoption of this ASU should be applied prospectively, but may be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard on the Company’s financial statement disclosures and expects the standard will increase disclosures in the Company’s annual and interim reporting when adopted.
In December 2025, the FASB issued ASU 2025-10, Accounting for Government Grants Received by Business Entities, which establishes authoritative guidance on the accounting for government grants to business entities. ASU 2025-10 is effective for annual and interim periods beginning after December 15, 2028. Adoption of this ASU may be applied using a modified prospective, modified retrospective or retrospective approach. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard on the Company’s financial statement disclosures, but does not expect the impact to be material.
2. Acquisitions and Divestitures
All of the Company’s acquisitions of businesses have been accounted for under Accounting Standards Codification (“ASC”) 805, Business Combinations. Accordingly, the assets and liabilities of the acquired companies, after adjustments to reflect the fair values assigned to the assets and liabilities, have been included in the Condensed Consolidated Balance Sheets from their respective dates of acquisition. The results of operations of businesses acquired have been included in the Condensed Consolidated Statements of Income since their respective dates of acquisition. Supplemental pro forma information has not been provided as the acquisitions did not have a material impact on the Condensed Consolidated Financial Statements individually or in the aggregate.
The Company makes a preliminary allocation of the purchase price for each acquisition as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities. These nonrecurring fair value measurements are classified as Level 3 in the fair value hierarchy. As the Company continues to obtain additional information, primarily related to the valuations of these assets and liabilities, and continues to integrate the newly acquired business, the Company will refine the estimates of fair value and more accurately allocate the purchase price through the completion of the measurement period, which is not to exceed one year from the date of acquisition. Only items that existed as of the acquisition date are considered for subsequent adjustment to the purchase price allocation. Goodwill recognized reflects the strategic fit, revenue and earnings growth potential of the acquired business and its synergies with existing IDEX businesses.
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions, except per share amounts)
(unaudited)
2025 Acquisitions
Micro-LAM, Inc.
On July 29, 2025, the Company acquired Micro-LAM, Inc. (“Micro-LAM”) in a stock acquisition. Micro-LAM is an advanced optics manufacturer of laser-assisted machining, ultra-precision diamond tools and custom optics that is complementary to the Company’s Optics Technologies solutions. Headquartered in Portage, Michigan, Micro-LAM operates in the Company’s Scientific Fluidics & Optics reporting unit within the Health & Science Technologies segment. Micro-LAM was acquired for cash consideration of $80.4 million, net of cash acquired of $0.3 million, plus a potential earnout of up to $12.0 million of additional cash consideration based upon the achievement of certain financial performance targets over a two-year period. Total consideration of $81.6 million includes the fair value of the potential earnout as of the acquisition date of $1.2 million. For additional discussion of the earnout valuation, refer to Note 9, “Fair Value Measurements.” The acquisition was funded using additional borrowings under the Company’s Revolving Facility (as defined in Note 8, “Borrowings”). Goodwill and intangible assets recognized as part of this transaction were $37.2 million and $44.6 million, respectively. The goodwill is not deductible for tax purposes.
As of March 31, 2026, the preliminary allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:
| Total | |||||
| Current assets, net of cash acquired | $ | 7.5 | |||
| Property, plant and equipment | 8.1 | ||||
| Goodwill | 37.2 | ||||
| Intangible assets | 44.6 | ||||
| Other noncurrent assets | 2.9 | ||||
| Total assets acquired | 100.3 | ||||
| Current liabilities | (6.2) | ||||
| Deferred income taxes | (9.9) | ||||
| Other noncurrent liabilities | (2.6) | ||||
| Net assets acquired(1) | $ | 81.6 |
(1) During the fourth quarter of 2025, the Company finalized the purchase price of Micro-LAM, resulting in a reduction to the purchase price of $0.3 million.
The acquired intangible assets and weighted average amortization periods are as follows:
| Total | Weighted Average Life (in years) | ||||||||||
| Trade names | $ | 5.3 | 15 | ||||||||
| Customer relationships | 20.9 | 11 | |||||||||
| Technology | 18.4 | 12 | |||||||||
| Acquired intangible assets | $ | 44.6 |
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions, except per share amounts)
(unaudited)
Acquisition-Related Costs
The Company incurred acquisition-related costs of $0.5 million and $0.7 million during the three months ended March 31, 2026 and 2025, respectively. These costs were recorded in Selling, general and administrative expenses and were related to completed, pending and potential transactions, including transactions that ultimately were not completed. There were no fair value inventory step-up charges recorded during the three months ended March 31, 2026 and 2025.
3. Business Segments
IDEX has three reportable business segments: Health & Science Technologies (“HST”), Fluid & Metering Technologies (“FMT”), and Fire & Safety/Diversified Products (“FSDP”).
The Company uses Adjusted EBITDA as its measure of segment performance. Intersegment sales are contracted with terms equivalent to those of an arm’s-length transaction. Information on the Company’s business segments is presented below.
| Three Months Ended March 31, 2026 | |||||||||||||||||||||||||||||||||||
| HST | FMT | FSDP | Total Segments | Eliminations | IDEX | ||||||||||||||||||||||||||||||
| NET SALES | |||||||||||||||||||||||||||||||||||
| External customers | $ | 397.4 | $ | 301.3 | $ | 188.2 | $ | 886.9 | $ | — | $ | 886.9 | |||||||||||||||||||||||
| Intersegment sales | 1.0 | 0.2 | 0.1 | 1.3 | (1.3) | — | |||||||||||||||||||||||||||||
| Net sales | 398.4 | 301.5 | 188.3 | 888.2 | (1.3) | 886.9 | |||||||||||||||||||||||||||||
| Adjusted segment cost of sales(1) | (231.3) | (155.3) | (103.5) | (490.1) | 1.3 | (488.8) | |||||||||||||||||||||||||||||
| Other segment expenses(2) | (61.1) | (47.5) | (29.0) | (137.6) | |||||||||||||||||||||||||||||||
| Segment Adjusted EBITDA | $ | 106.0 | $ | 98.7 | $ | 55.8 | $ | 260.5 |
| Three Months Ended March 31, 2025 | |||||||||||||||||||||||||||||||||||
| HST | FMT | FSDP | Total Segments | Eliminations | IDEX | ||||||||||||||||||||||||||||||
| NET SALES | |||||||||||||||||||||||||||||||||||
| External customers | $ | 340.1 | $ | 290.2 | $ | 184.0 | $ | 814.3 | $ | — | $ | 814.3 | |||||||||||||||||||||||
| Intersegment sales | 1.4 | 0.3 | 0.3 | 2.0 | (2.0) | — | |||||||||||||||||||||||||||||
| Net sales | 341.5 | 290.5 | 184.3 | 816.3 | (2.0) | 814.3 | |||||||||||||||||||||||||||||
| Adjusted segment cost of sales(1) | (201.2) | (146.3) | (99.9) | (447.4) | 2.0 | (445.4) | |||||||||||||||||||||||||||||
| Other segment expenses(2) | (52.9) | (48.9) | (30.2) | (132.0) | |||||||||||||||||||||||||||||||
| Segment Adjusted EBITDA | $ | 87.4 | $ | 95.3 | $ | 54.2 | $ | 236.9 |
(1) Adjusted segment cost of sales represents Cost of sales excluding fair value inventory step-up charges. There were no step-up charges during the three months ended March 31, 2026 or 2025.
(2) Other segment expenses consists primarily of selling, general and administrative expenses.
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions, except per share amounts)
(unaudited)
| Three Months Ended March 31, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| ADJUSTED EBITDA | |||||||||||||||||||||||
| Health & Science Technologies | $ | 106.0 | $ | 87.4 | |||||||||||||||||||
| Fluid & Metering Technologies | 98.7 | 95.3 | |||||||||||||||||||||
| Fire & Safety/Diversified Products | 55.8 | 54.2 | |||||||||||||||||||||
| Segment Adjusted EBITDA | 260.5 | 236.9 | |||||||||||||||||||||
| Corporate and other(1) | (30.1) | (28.9) | |||||||||||||||||||||
| Interest expense – net | (16.0) | (16.1) | |||||||||||||||||||||
| Depreciation(3) | (19.9) | (18.4) | |||||||||||||||||||||
| Amortization of intangible assets(3) | (33.8) | (31.5) | |||||||||||||||||||||
| Restructuring expenses and asset impairments | (7.4) | (17.5) | |||||||||||||||||||||
| Gain on legal settlement(2) | 3.7 | — | |||||||||||||||||||||
| Income before income taxes | $ | 157.0 | $ | 124.5 |
(1) Corporate expenses that can be identified with a segment have been included in determining segment results. The remainder are included in Corporate and other.
(2) Gain on legal settlement represents settlement funds received in excess of legal costs incurred related to a patent infringement lawsuit.
(3) Depreciation and amortization of intangible assets by segment for the three months ended March 31, 2026 and 2025 was:
| Three Months Ended March 31, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| DEPRECIATION | |||||||||||||||||||||||
| Health & Science Technologies | $ | 12.5 | $ | 11.7 | |||||||||||||||||||
| Fluid & Metering Technologies | 4.9 | 4.4 | |||||||||||||||||||||
| Fire & Safety/Diversified Products | 2.4 | 2.2 | |||||||||||||||||||||
| Total Segments | 19.8 | 18.3 | |||||||||||||||||||||
| Corporate and other | 0.1 | 0.1 | |||||||||||||||||||||
| Total depreciation | $ | 19.9 | $ | 18.4 | |||||||||||||||||||
| AMORTIZATION OF INTANGIBLE ASSETS | |||||||||||||||||||||||
| Health & Science Technologies | $ | 27.1 | $ | 24.6 | |||||||||||||||||||
| Fluid & Metering Technologies | 5.4 | 5.3 | |||||||||||||||||||||
| Fire & Safety/Diversified Products | 1.3 | 1.6 | |||||||||||||||||||||
| Total amortization | $ | 33.8 | $ | 31.5 |
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions, except per share amounts)
(unaudited)
| March 31, 2026 | December 31, 2025 | ||||||||||
| ASSETS | |||||||||||
| Health & Science Technologies | $ | 4,292.9 | $ | 4,301.1 | |||||||
| Fluid & Metering Technologies | 1,677.8 | 1,694.4 | |||||||||
| Fire & Safety/Diversified Products | 822.7 | 825.2 | |||||||||
| Total Segments | 6,793.4 | 6,820.7 | |||||||||
| Corporate and other | 125.2 | 106.3 | |||||||||
| Total assets | $ | 6,918.6 | $ | 6,927.0 |
4. Revenue
Disaggregation of Revenue
The Company has a comprehensive offering of products, including technologies, built to customers’ specifications that are sold in niche markets throughout the world. The Company disaggregates revenue from contracts with customers by reporting unit and geographical region for each segment as the Company believes it best depicts how the amount, nature, timing and uncertainty of its revenue and cash flows are affected by economic factors. Revenue, presented as Net sales on the Condensed Consolidated Statements of Income, was attributed to geographical region based on the location of the customer. The following tables present revenue disaggregated by reporting unit and geographical region.
Revenue by reporting unit for the three months ended March 31, 2026 and 2025 was as follows:
| Three Months Ended March 31, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| Scientific Fluidics & Optics | $ | 214.1 | $ | 194.0 | |||||||||||||||||||
| Performance Pneumatic Technologies | 83.3 | 59.0 | |||||||||||||||||||||
| Sealing Solutions | 69.7 | 60.6 | |||||||||||||||||||||
| Material Processing Technologies | 31.3 | 27.9 | |||||||||||||||||||||
| Intersegment elimination | (1.0) | (1.4) | |||||||||||||||||||||
| Health & Science Technologies | 397.4 | 340.1 | |||||||||||||||||||||
| Pumps | 108.4 | 105.8 | |||||||||||||||||||||
| Water | 89.6 | 82.9 | |||||||||||||||||||||
| Energy | 50.0 | 46.9 | |||||||||||||||||||||
| Agriculture | 33.1 | 32.0 | |||||||||||||||||||||
| Valves | 20.4 | 22.9 | |||||||||||||||||||||
| Intersegment elimination | (0.2) | (0.3) | |||||||||||||||||||||
| Fluid & Metering Technologies | 301.3 | 290.2 | |||||||||||||||||||||
| Fire & Safety | 124.2 | 111.0 | |||||||||||||||||||||
| Dispensing | 34.1 | 43.6 | |||||||||||||||||||||
| BAND-IT | 30.0 | 29.7 | |||||||||||||||||||||
| Intersegment elimination | (0.1) | (0.3) | |||||||||||||||||||||
| Fire & Safety/Diversified Products | 188.2 | 184.0 | |||||||||||||||||||||
| Net sales | $ | 886.9 | $ | 814.3 |
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions, except per share amounts)
(unaudited)
Revenue by geographical region for the three months ended March 31, 2026 and 2025 was as follows:
| Three Months Ended March 31, 2026 | |||||||||||||||||||||||
| HST | FMT | FSDP | IDEX | ||||||||||||||||||||
| U.S. | $ | 185.7 | $ | 175.7 | $ | 95.7 | $ | 457.1 | |||||||||||||||
| North America, excluding U.S. | 5.8 | 15.2 | 7.5 | 28.5 | |||||||||||||||||||
| Europe | 122.8 | 53.8 | 48.7 | 225.3 | |||||||||||||||||||
| Asia | 74.3 | 34.3 | 27.1 | 135.7 | |||||||||||||||||||
| Other(1) | 9.8 | 22.5 | 9.3 | 41.6 | |||||||||||||||||||
| Intersegment elimination | (1.0) | (0.2) | (0.1) | (1.3) | |||||||||||||||||||
| Net sales | $ | 397.4 | $ | 301.3 | $ | 188.2 | $ | 886.9 |
| Three Months Ended March 31, 2025 | |||||||||||||||||||||||
| HST | FMT | FSDP | IDEX | ||||||||||||||||||||
| U.S. | $ | 155.1 | $ | 168.8 | $ | 95.5 | $ | 419.4 | |||||||||||||||
| North America, excluding U.S. | 4.7 | 16.0 | 8.1 | 28.8 | |||||||||||||||||||
| Europe | 102.1 | 48.4 | 42.5 | 193.0 | |||||||||||||||||||
| Asia | 71.3 | 34.4 | 31.0 | 136.7 | |||||||||||||||||||
| Other(1) | 8.3 | 22.9 | 7.2 | 38.4 | |||||||||||||||||||
| Intersegment elimination | (1.4) | (0.3) | (0.3) | (2.0) | |||||||||||||||||||
| Net sales | $ | 340.1 | $ | 290.2 | $ | 184.0 | $ | 814.3 |
(1) Other includes: South America, Middle East, Australia and Africa.
Performance Obligations
The Company’s performance obligations are satisfied either at a point in time or over time as work progresses. Revenue from products and services transferred to customers at a point in time comprised approximately 95% of the Company’s revenue and over time comprised approximately 5% of the Company’s revenue for both the three months ended March 31, 2026 and 2025.
Contract Assets and Liabilities
The timing of billings and cash collections can result in customer receivables, billings in excess of revenue recognized, advance payments or deposits. Customer receivables include both amounts billed and currently due from customers as well as unbilled amounts (contract assets) and are included in Receivables – net on the Condensed Consolidated Balance Sheets.
The composition of customer receivables was as follows:
| March 31, 2026 | December 31, 2025 | ||||||||||
| Billed receivables | $ | 515.0 | $ | 477.1 | |||||||
| Unbilled receivables | 29.5 | 34.8 | |||||||||
| Total customer receivables | $ | 544.5 | $ | 511.9 |
Billings in excess of revenue recognized, advance payments and deposits represent contract liabilities and are included in deferred revenue which is classified as current or noncurrent based on when the Company expects to recognize the revenue. The current portion is included in Accrued expenses and the noncurrent portion is included in Other noncurrent liabilities on the Condensed Consolidated Balance Sheets.
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions, except per share amounts)
(unaudited)
The composition of deferred revenue was as follows:
| March 31, 2026 | December 31, 2025 | ||||||||||
| Deferred revenue – current | $ | 50.9 | $ | 45.8 | |||||||
| Deferred revenue – noncurrent | 20.6 | 22.0 | |||||||||
| Total deferred revenue | $ | 71.5 | $ | 67.8 |
5. Earnings Per Common Share
Diluted earnings per common share (“EPS”) attributable to IDEX is computed by dividing Net income attributable to IDEX by the weighted average number of common shares outstanding (basic) plus common stock equivalents outstanding (diluted) for the period. Common stock equivalents consist of restricted stock, performance share units and stock options, which have been included in the calculation of weighted average common shares outstanding using the treasury stock method.
Outstanding unvested share-based payment awards that contain rights to non-forfeitable dividends participate in undistributed earnings with common shareholders. If awards are considered participating securities, the Company is required to apply the two-class method of computing basic and diluted earnings per share. The Company has both participating and non-participating securities. Dividend rights for restricted stock awards issued under the IDEX Corporation 2024 Incentive Award Plan (the “2024 Incentive Award Plan”) are subject to the same vesting requirements as the underlying restricted stock awards, and therefore, these awards are considered non-participating securities. Dividend rights for restricted stock awards issued prior to the adoption of the 2024 Incentive Award Plan are non-forfeitable and are not subject to the same vesting requirements as the underlying restricted stock awards. As such, these awards have been determined to be participating securities. Accordingly, Diluted EPS attributable to IDEX was computed using the two-class method.
Basic weighted average common shares outstanding reconciles to diluted weighted average common shares outstanding as follows:
| Three Months Ended March 31, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| Basic weighted average common shares outstanding | 74.3 | 75.7 | |||||||||||||||||||||
| Dilutive effect of restricted stock, performance share units and stock options | 0.1 | 0.1 | |||||||||||||||||||||
| Diluted weighted average common shares outstanding | 74.4 | 75.8 |
Share-based payment awards of approximately 0.6 million and 0.5 million shares of common stock for the three months ended March 31, 2026 and 2025, respectively, were not included in the computation of Diluted EPS attributable to IDEX because the effect of their inclusion would have been antidilutive.
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions, except per share amounts)
(unaudited)
6. Balance Sheet Components
| March 31, 2026 | December 31, 2025 | ||||||||||
| RECEIVABLES – NET | |||||||||||
| Customers | $ | 544.5 | $ | 511.9 | |||||||
| Other | 19.5 | 19.2 | |||||||||
| Total | 564.0 | 531.1 | |||||||||
| Less: allowance for credit losses | 11.0 | 9.4 | |||||||||
| Receivables – net | $ | 553.0 | $ | 521.7 | |||||||
| INVENTORIES – NET | |||||||||||
| Raw materials and component parts | $ | 322.6 | $ | 316.1 | |||||||
| Work in process | 57.7 | 47.7 | |||||||||
| Finished goods | 120.7 | 115.6 | |||||||||
| Inventories – net | $ | 501.0 | $ | 479.4 | |||||||
| ACCRUED EXPENSES | |||||||||||
| Payroll and related items | $ | 90.9 | $ | 112.2 | |||||||
| Management incentive compensation | 7.9 | 19.1 | |||||||||
| Income taxes payable | 25.4 | 14.0 | |||||||||
| Warranty | 13.5 | 14.4 | |||||||||
| Deferred revenue | 50.9 | 45.8 | |||||||||
| Lease liability | 27.0 | 27.8 | |||||||||
| Restructuring | 1.4 | 3.0 | |||||||||
| Accrued interest | 13.9 | 11.7 | |||||||||
| Other | 49.7 | 49.0 | |||||||||
| Accrued expenses | $ | 280.6 | $ | 297.0 | |||||||
7. Goodwill and Intangible Assets
The changes in the carrying amount of goodwill for the three months ended March 31, 2026, by reportable business segment, were as follows:
| HST | FMT | FSDP | IDEX | ||||||||||||||||||||
| Goodwill | $ | 2,406.5 | $ | 801.7 | $ | 406.9 | $ | 3,615.1 | |||||||||||||||
| Accumulated goodwill impairment losses | (149.8) | (20.7) | (30.1) | (200.6) | |||||||||||||||||||
| Balance at January 1, 2026 | 2,256.7 | 781.0 | 376.8 | 3,414.5 | |||||||||||||||||||
| Foreign currency translation | (17.9) | (3.3) | (3.3) | (24.5) | |||||||||||||||||||
| Measurement period adjustments | 0.2 | — | — | 0.2 | |||||||||||||||||||
| Balance at March 31, 2026 | $ | 2,239.0 | $ | 777.7 | $ | 373.5 | $ | 3,390.2 |
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions, except per share amounts)
(unaudited)
The following table provides the gross carrying value and accumulated amortization for each major class of intangible asset at March 31, 2026 and December 31, 2025:
| March 31, 2026 | December 31, 2025 | ||||||||||||||||||||||||||||||||||
| Gross Carrying Amount | Accumulated Amortization | Net | Gross Carrying Amount | Accumulated Amortization | Net | ||||||||||||||||||||||||||||||
| Amortized intangible assets: | |||||||||||||||||||||||||||||||||||
| Trade names(1) | $ | 200.0 | $ | (68.1) | $ | 131.9 | $ | 209.7 | $ | (71.4) | $ | 138.3 | |||||||||||||||||||||||
| Customer relationships(1) | 1,132.8 | (396.3) | 736.5 | 1,148.4 | (380.9) | 767.5 | |||||||||||||||||||||||||||||
| Technology | 339.3 | (106.4) | 232.9 | 344.3 | (102.3) | 242.0 | |||||||||||||||||||||||||||||
| Software | 16.0 | (8.0) | 8.0 | 16.0 | (7.3) | 8.7 | |||||||||||||||||||||||||||||
| Total amortized intangible assets | 1,688.1 | (578.8) | 1,109.3 | 1,718.4 | (561.9) | 1,156.5 | |||||||||||||||||||||||||||||
| Indefinite-lived intangible assets: | |||||||||||||||||||||||||||||||||||
| Banjo trade name | 62.1 | — | 62.1 | 62.1 | — | 62.1 | |||||||||||||||||||||||||||||
| Akron Brass trade name | 28.8 | — | 28.8 | 28.8 | — | 28.8 | |||||||||||||||||||||||||||||
| Total intangible assets | $ | 1,779.0 | $ | (578.8) | $ | 1,200.2 | $ | 1,809.3 | $ | (561.9) | $ | 1,247.4 |
(1) During the three months ended March 31, 2026, the Company recognized impairment charges of $1.1 million and $3.2 million related to trade names and customer relationships, respectively, in the Company’s FMT segment. The impairment charge is included in Restructuring expenses and asset impairments in the Condensed Consolidated Statements of Income.
Other than noted above, there have been no events or circumstances since the last annual assessment date, October 31, 2025, that would have required an interim impairment test.
Amortization of intangible assets was $33.8 million and $31.5 million for the three months ended March 31, 2026 and 2025, respectively. Based on the intangible asset balances as of March 31, 2026, expected amortization expense for the remaining nine months of 2026 and for the years 2027 through 2030 is as follows:
| Estimated Amortization | ||||||||
| Remainder of 2026 | $ | 98.1 | ||||||
| 2027 | 126.8 | |||||||
| 2028 | 124.0 | |||||||
| 2029 | 113.8 | |||||||
| 2030 | 105.4 |
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions, except per share amounts)
(unaudited)
8. Borrowings
Borrowings at March 31, 2026 and December 31, 2025 consisted of the following:
| March 31, 2026 | December 31, 2025 | ||||||||||
| 5.13% Senior Notes, due June 2028 (the “5.13% Senior Notes”) | 100.0 | 100.0 | |||||||||
| 4.950% Senior Notes, due September 2029 (the “4.950% Senior Notes”) | 500.0 | 500.0 | |||||||||
| 3.00% Senior Notes, due May 2030 (the “3.00% Senior Notes”) | 500.0 | 500.0 | |||||||||
| 2.625% Senior Notes, due June 2031 (the “2.625% Senior Notes”) | 500.0 | 500.0 | |||||||||
| $800.0 million Revolving Facility, due November 2027 (the “Revolving Facility”)(1) | 280.1 | 228.8 | |||||||||
| Other borrowings | 0.7 | 1.0 | |||||||||
| Total borrowings | 1,880.8 | 1,829.8 | |||||||||
| Less: current portion | 0.5 | 0.7 | |||||||||
| Less: unamortized debt issuance costs and discount on debt | 8.5 | 9.0 | |||||||||
| Long-term borrowings | $ | 1,871.8 | $ | 1,820.1 |
(1) At March 31, 2026, there was $280.1 million outstanding under the Revolving Facility and $2.7 million of outstanding letters of credit, resulting in a net available borrowing capacity under the Revolving Facility of approximately $517.2 million. During the first quarter of 2026, the Company drew down an aggregate amount of $100.0 million under the Revolving Facility which was used for general corporate purposes, including to finance share repurchases. The Company repaid $45.3 million under the Revolving Facility during the first quarter of 2026. The weighted-average interest rate for borrowings outstanding under the Revolving Facility was 3.68% for the three months ended March 31, 2026 and 3.55% for the year ended December 31, 2025.
9. Fair Value Measurements
The accounting guidance for fair value measurements and disclosures establishes a three-level fair value hierarchy:
-
Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
-
Level 2: Inputs, other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
-
Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions, except per share amounts)
(unaudited)
The following table summarizes the basis used to measure the Company’s financial assets and liabilities at fair value on a recurring basis in the balance sheets at March 31, 2026 and December 31, 2025:
| March 31, 2026 | |||||||||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||
| Assets | |||||||||||||||||||||||
| Trading securities - mutual funds held in nonqualified SERP(1) | $ | 10.3 | $ | — | $ | — | $ | 10.3 | |||||||||||||||
| Liabilities | |||||||||||||||||||||||
| Contingent consideration(2) | — | — | 1.2 | 1.2 | |||||||||||||||||||
| December 31, 2025 | |||||||||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||
| Assets | |||||||||||||||||||||||
| Trading securities - mutual funds held in nonqualified SERP(1) | $ | 10.8 | $ | — | $ | — | $ | 10.8 | |||||||||||||||
| Liabilities | |||||||||||||||||||||||
| Contingent consideration(2) | — | — | 1.2 | 1.2 |
(1) The Supplemental Executive Retirement Plan (“SERP”) investment assets are offset by a SERP liability which represents the Company’s obligation to distribute SERP funds to participants. The SERP investment assets and liability are included in Other noncurrent assets and Other noncurrent liabilities, respectively, on the Condensed Consolidated Balance Sheets.
(2) In connection with the acquisition of Micro-LAM, the Company entered into an earnout agreement that may require us to make future cash consideration payments of up to $12.0 million based upon the achievement of certain financial performance targets from January 1, 2026 to December 31, 2027. As of March 31, 2026, $0.4 million of contingent consideration related to the Micro-LAM acquisition has been included in Accrued expenses and $0.8 million has been included in Other noncurrent liabilities on the Condensed Consolidated Balance Sheets. As of December 31, 2025, $1.2 million of contingent consideration related to the Micro-LAM acquisition was included in Other noncurrent liabilities on the Condensed Consolidated Balance Sheets. The contingent consideration was derived using a Monte Carlo simulation model which utilizes inputs including discount rates, volatility rates, and estimated probability of achieving projected revenue and profitability targets. This fair value measurement of contingent consideration is categorized within Level 3 of the fair value hierarchy, as the measurement amount is based primarily on significant inputs that are not observable in the market. The fair value of the contingent consideration is re-measured at each reporting period, and the change in fair value is recognized within Selling, general and administrative expenses in the Condensed Consolidated Statements of Income. There was no change in the fair value measurement of contingent consideration during the three months ended March 31, 2026.
There were no transfers of assets or liabilities between Level 1, Level 2 and Level 3 during the three months ended March 31, 2026 or the year ended December 31, 2025.
The carrying values of the Company’s other financial instruments (i.e., cash and cash equivalents, accounts receivable, accounts payable and accrued expenses) approximate fair value because of the short-term nature of these instruments.
Certain non-financial assets, primarily property, plant and equipment, goodwill and intangible assets, are not required to be measured at fair value on a recurring basis and are reported at their carrying value. However, these assets are required to be assessed for impairment whenever events or circumstances indicate that their carrying value may not be fully recoverable, and at least annually for goodwill and indefinite-lived intangible assets. See Note 7, “Goodwill and Intangible Assets,” for additional information about these assets.
The following table provides the fair value of the outstanding indebtedness described in Note 8, “Borrowings,” which is based on quoted market prices and current market rates for debt with similar credit risk and maturity, as well as the carrying value. These fair value measurements are classified as Level 2 within the fair value hierarchy since they are determined based
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions, except per share amounts)
(unaudited)
upon significant inputs observable in the market, including interest rates on recent financing transactions to entities with a credit rating similar to the Company’s rating.
| March 31, 2026 | December 31, 2025 | ||||||||||||||||||||||||||||||||||
| Fair Value | Carrying Amount | Fair Value | Carrying Amount | ||||||||||||||||||||||||||||||||
| Total Borrowings, less unaccreted debt discount | $ | 1,808.8 | $ | 1,879.8 | $ | 1,773.9 | $ | 1,828.8 |
10. Accumulated Other Comprehensive Income (Loss)
The components of Accumulated other comprehensive income (loss) for the three months ended March 31, 2026 and 2025 are as follows:
| Cumulative Translation Adjustment | Pension and Other Postretirement Adjustments | Accumulated Other Comprehensive Income (Loss) | ||||||||||||||||||
| Three Months Ended March 31, 2026 | ||||||||||||||||||||
| Balance, December 31, 2025(1) | $ | 48.8 | $ | 8.8 | $ | 57.6 | ||||||||||||||
| Other comprehensive loss before reclassification adjustments | (43.5) | — | (43.5) | |||||||||||||||||
| Gain reclassified from Accumulated other comprehensive income(2)(3) | (0.2) | (0.2) | ||||||||||||||||||
| Tax impact | — | — | ||||||||||||||||||
| Net other comprehensive loss(1) | (43.5) | (0.2) | (43.7) | |||||||||||||||||
| Balance, March 31, 2026(1) | $ | 5.3 | $ | 8.6 | $ | 13.9 |
| Three Months Ended March 31, 2025 | ||||||||||||||||||||
| Balance, December 31, 2024(1) | $ | (137.5) | $ | 6.6 | $ | (130.9) | ||||||||||||||
| Other comprehensive income before reclassification adjustments | 53.9 | — | 53.9 | |||||||||||||||||
| Gain reclassified from Accumulated other comprehensive loss(2)(3) | — | (0.2) | (0.2) | |||||||||||||||||
| Tax impact | — | — | — | |||||||||||||||||
| Net other comprehensive income (loss)(1) | 53.9 | (0.2) | 53.7 | |||||||||||||||||
| Balance, March 31, 2025(1) | $ | (83.6) | $ | 6.4 | $ | (77.2) |
(1) Amounts are presented net of tax.
(2) Included in the computation of net periodic cost. See Note 13, “Retirement Benefits.”
(3) Included in Other (income) expense – net in the Condensed Consolidated Statements of Income.
11. Share Repurchases
On September 17, 2025, the Company’s Board of Directors authorized the repurchase of an additional $635.0 million of the Company’s common shares. This approval is in addition to the prior repurchase authorization of the Company’s Board of Directors of $500.0 million on March 17, 2020. These authorizations have no expiration date. During the three months ended March 31, 2026, the Company repurchased a total of 0.4 million shares at a cost of $75.6 million (including estimated excise taxes of $0.6 million, which will be paid in 2027), of which $0.9 million was settled in April 2026. During the three months ended March 31, 2025, the Company repurchased a total of 0.3 million shares at a cost of $50.4 million (including estimated excise taxes of $0.4 million). As of March 31, 2026, the amount of share repurchase authorization remaining was $849.7 million, excluding fees, commissions, excise taxes and other expenses related to such common stock repurchases.
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions, except per share amounts)
(unaudited)
12. Share-Based Compensation
The Company typically grants equity awards annually at its regularly scheduled first quarter meeting of the Board of Directors based on the recommendation from the Compensation Committee.
Stock Options
Stock options granted under the Company’s plans are generally non-qualified and are granted with an exercise price equal to the market price of the Company’s stock on the date of grant. The fair value of each option grant in the periods presented was estimated on the date of the grant using the Black Scholes valuation model. Stock options generally vest annually in equal amounts over four years, with vesting beginning one year from the date of grant, and generally expire 10 years from the date of grant. The service period for certain retiree eligible participants is accelerated. The assumptions used in determining the fair value of the stock options granted in the respective periods were as follows:
| Three Months Ended March 31, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| Weighted average fair value of grants | $49.18 | $46.74 | |||||||||||||||||||||
| Dividend yield | 1.37% | 1.41% | |||||||||||||||||||||
| Volatility | 23.80% | 23.06% | |||||||||||||||||||||
| Risk-free interest rate | 3.61% | 4.28% | |||||||||||||||||||||
| Expected life (in years) | 4.90 | 4.70 |
A summary of the Company’s stock option activity as of March 31, 2026 and changes during the three months ended March 31, 2026 are presented in the following table:
| Stock Options | Shares | Weighted Average Exercise Price | Weighted-Average Remaining Contractual Term (years) | Aggregate Intrinsic Value | |||||||||||||||||||
| Outstanding at January 1, 2026 | 954,201 | $ | 192.03 | 5.82 | $ | 8.9 | |||||||||||||||||
| Granted | 85,270 | 207.69 | |||||||||||||||||||||
| Exercised | (44,656) | 158.16 | |||||||||||||||||||||
| Forfeited | (16,795) | 220.65 | |||||||||||||||||||||
| Outstanding at March 31, 2026 | 978,020 | $ | 194.45 | 6.00 | $ | 10.5 | |||||||||||||||||
| Vested and expected to vest as of March 31, 2026 | 963,397 | $ | 194.14 | 5.96 | $ | 10.5 | |||||||||||||||||
| Exercisable at March 31, 2026 | 741,704 | $ | 187.74 | 5.15 | $ | 10.5 |
As of March 31, 2026, there was $4.9 million of total unrecognized compensation cost related to stock options that is expected to be recognized over a weighted-average period of 1.3 years.
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions, except per share amounts)
(unaudited)
Restricted Stock
Restricted stock awards granted beginning in 2026 generally vest annually in equal amounts over three years, with vesting beginning one year from the date of the grant. Restricted stock awards granted prior to 2026 generally cliff vest after three years for employees. Restricted stock awards granted to non-employee directors generally cliff vest after one year. The service period for certain retiree eligible participants is accelerated. Unvested restricted stock granted after the adoption of the 2024 Incentive Award Plan earn dividend equivalents for the award period, which will be paid to participants upon vesting of the underlying awards. Unvested restricted stock granted prior to the adoption of the 2024 Incentive Award Plan earn and are paid dividends. The fair value of restricted stock is equal to the market price of the Company’s stock at the date of the grant. A summary of the Company’s restricted stock activity as of March 31, 2026 and changes during the three months ended March 31, 2026 are presented in the following table:
| Restricted Stock | Shares | Weighted-Average Grant Date Fair Value | |||||||||
| Unvested at January 1, 2026 | 190,822 | $ | 198.64 | ||||||||
| Granted | 84,665 | 202.48 | |||||||||
| Vested | (15,828) | 220.38 | |||||||||
| Forfeited | (13,348) | 203.35 | |||||||||
| Unvested at March 31, 2026 | 246,311 | $ | 198.31 |
As of March 31, 2026, there was $23.3 million of total unrecognized compensation cost related to restricted stock that is expected to be recognized over a weighted-average period of 1.1 years.
Cash-Settled Restricted Stock
The Company also maintains a cash-settled share-based compensation plan for certain employees. Cash-settled restricted stock awards granted under the 2024 Incentive Plan beginning in 2026 generally vest annually in equal amounts over three years, with vesting beginning one year from the date of grant. Cash-settled restricted stock awards granted prior to 2026 generally cliff vest after three years. The service period for certain retiree eligible participants is accelerated. Cash-settled restricted stock awards are recorded at fair value on a quarterly basis using the market price of the Company’s stock on the last day of the quarter. At March 31, 2026 and December 31, 2025, the Company had accrued $3.7 million and $3.6 million, respectively, for cash-settled restricted stock in Accrued expenses in the Condensed Consolidated Balance Sheets and had accrued $1.6 million and $2.4 million, respectively, for cash-settled restricted stock in Other noncurrent liabilities in the Condensed Consolidated Balance Sheets. These recurring fair value measurements are classified as Level 1 in the fair value hierarchy. Dividend equivalents are earned throughout the award period and paid upon vesting for certain cash-settled restricted stock awards granted after the adoption of the 2024 Incentive Award Plan. Dividend equivalents are paid on certain cash-settled restricted stock awards granted prior to the adoption of the 2024 Incentive Award Plan. A summary of the Company’s unvested cash-settled restricted stock activity as of March 31, 2026 and changes during the three months ended March 31, 2026 are presented in the following table:
| Cash-Settled Restricted Stock | Shares | Weighted-Average Fair Value | |||||||||
| Unvested at January 1, 2026 | 62,292 | $ | 177.94 | ||||||||
| Granted | 30,750 | 207.86 | |||||||||
| Vested | (14,080) | 206.60 | |||||||||
| Forfeited | (1,160) | 189.55 | |||||||||
| Unvested at March 31, 2026 | 77,802 | $ | 189.55 |
As of March 31, 2026, there was $7.4 million of total unrecognized compensation cost related to cash-settled restricted stock that is expected to be recognized over a weighted-average period of 1.3 years.
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions, except per share amounts)
(unaudited)
Performance Share Units
Performance share unit awards represent rights to receive shares of the Company’s common stock and will vest between 0% to 250% of the target share unit amount. Performance share units granted after December 31, 2024 are earned over a three-year performance period based on an internal income growth metric (a performance condition), weighted 25%. The remaining 75% of the award is earned based on a market condition, which is the total shareholder return of IDEX common stock in relation to the total shareholder return of a group of peer companies (for awards granted in 2025, the peer group consists of companies in the S&P 500 index, and for awards granted beginning in 2026, the peer group consists of companies in the S&P 900 Capital Goods and Life Sciences Tools & Services indexes). Performance share unit awards granted prior to 2025 are earned solely based on the Company’s total shareholder return ranking in relation to the total shareholder return of companies in the S&P 500 Index over a three-year period following the date of grant.
The fair value of the performance condition portion of the awards granted after December 31, 2024 is equal to the market price of the Company’s stock at the date of the grant, and the amount of expense recognized over the vesting period is subject to adjustment based on the expected attainment of the performance condition. The fair value of the market condition portion of all performance share unit awards is determined using a Monte Carlo simulation model, and the amount of expense recognized over the vesting period is not subject to change based on future market conditions. The assumptions used in the Monte Carlo simulation model to determine the fair value of the market condition portion of the performance share units granted in the respective periods were as follows:
| Three Months Ended March 31, | |||||||||||
| 2026 | 2025 | ||||||||||
| Weighted average fair value of grants | $274.50 | $232.44 | |||||||||
| Dividend yield | —% | —% | |||||||||
| Volatility | 24.07% | 22.93% | |||||||||
| Risk-free interest rate | 3.47% | 4.23% | |||||||||
| Expected life (in years) | 2.95 | 2.94 |
A summary of the Company’s performance share unit activity as of March 31, 2026 and changes during the three months ended March 31, 2026 are presented in the following table:
| Performance Share Units | Shares | Weighted-Average Grant Date Fair Value | |||||||||
| Unvested at January 1, 2026 | 78,205 | $ | 267.78 | ||||||||
| Granted | 40,410 | 252.90 | |||||||||
| Vested | — | — | |||||||||
| Forfeited | (23,535) | 304.20 | |||||||||
| Unvested at March 31, 2026 | 95,080 | $ | 259.40 |
The performance period for the 2023 grants ended as of January 31, 2026. The 2023 grants achieved a 0% payout factor, and as such, the Company did not issue any shares of the Company's stock for awards that vested in 2026.
As of March 31, 2026, there was $5.2 million of total unrecognized compensation cost related to performance share units that is expected to be recognized over a weighted-average period of 1.3 years.
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions, except per share amounts)
(unaudited)
Summary of Share-Based Compensation Expense
The Company’s policy is to recognize compensation cost on a straight-line basis, assuming forfeitures, over the requisite service period for the entire award. Total compensation cost related to all share-based awards was as follows:
| Three Months Ended March 31, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| Stock options expense | $ | 3.1 | $ | 3.2 | |||||||||||||||||||
| Restricted stock expense | 6.5 | 5.5 | |||||||||||||||||||||
| Cash-settled restricted stock expense | 2.2 | 0.6 | |||||||||||||||||||||
| Performance share units expense | 6.2 | 4.9 | |||||||||||||||||||||
| Total pre-tax share-based compensation expense(1) | 18.0 | 14.2 | |||||||||||||||||||||
| Income tax benefit | (1.3) | (1.2) | |||||||||||||||||||||
| Total share-based compensation expense, net of income taxes | $ | 16.7 | $ | 13.0 |
(1) Pre-tax compensation cost is recognized in the Condensed Consolidated Statements of Income depending on the functional area of the underlying employees, as follows:
| Three Months Ended March 31, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| Cost of sales | $ | 1.1 | $ | 0.8 | |||||||||||||||||||
| Selling, general and administrative expenses | 16.9 | 14.0 | |||||||||||||||||||||
| Restructuring expenses and asset impairments(2) | — | (0.6) | |||||||||||||||||||||
| Total pre-tax share-based compensation expense | $ | 18.0 | $ | 14.2 |
(2) During the three months ended March 31, 2025, a benefit of $0.6 million was recognized in Restructuring expenses and asset impairments in the Condensed Consolidated Statements of Income related to forfeitures of share-based compensation awards resulting from restructuring actions initiated during the first quarter of 2025.
13. Retirement Benefits
The Company sponsors several qualified and nonqualified defined benefit and defined contribution pension plans as well as other postretirement plans for its employees. The following tables provide the components of net periodic cost for the Company’s major defined benefit plans and its other postretirement plans.
| Pension Benefits | |||||||||||||||||||||||
| Three Months Ended March 31, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| U.S. | Non-U.S. | U.S. | Non-U.S. | ||||||||||||||||||||
| Service cost | $ | — | $ | 0.3 | $ | — | $ | 0.3 | |||||||||||||||
| Interest cost | 0.1 | 0.6 | 0.1 | 0.6 | |||||||||||||||||||
| Expected return on plan assets | — | (0.5) | — | (0.5) | |||||||||||||||||||
| Net amortization | — | — | — | — | |||||||||||||||||||
| Net periodic cost | $ | 0.1 | $ | 0.4 | $ | 0.1 | $ | 0.4 |
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions, except per share amounts)
(unaudited)
| Other Postretirement Benefits | |||||||||||||||||||||||
| Three Months Ended March 31, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| Service cost | $ | 0.1 | $ | 0.1 | |||||||||||||||||||
| Interest cost | 0.2 | 0.2 | |||||||||||||||||||||
| Net amortization | (0.2) | (0.2) | |||||||||||||||||||||
| Net periodic cost | $ | 0.1 | $ | 0.1 |
The Company recognizes the service cost component in both Cost of sales and Selling, general and administrative expenses in the Condensed Consolidated Statements of Income depending on the functional area of the underlying employees and the interest cost, expected return on plan assets and net amortization components in Other (income) expense – net in the Condensed Consolidated Statements of Income.
The Company expects to contribute approximately $4.6 million to its defined benefit plans and $1.0 million to its other postretirement benefit plans in 2026. The Company contributed a total of $1.4 million and $1.2 million to fund these plans during the three months ended March 31, 2026 and 2025, respectively.
14. Commitments and Contingencies
The Company and certain of its subsidiaries are involved in pending and threatened legal, regulatory and other proceedings incidental to the operations of their businesses. These proceedings may pertain to matters such as product liability or contract disputes, and may also involve governmental inquiries, inspections, audits or investigations relating to issues such as tax matters, intellectual property, environmental, health and safety issues, governmental regulations, employment and other matters. Although the results of such legal proceedings cannot be predicted with certainty, the Company believes that the ultimate disposition of these matters will not have a material adverse effect, individually or in the aggregate, on the Company’s business, financial condition, results of operations or cash flows.
15. Income Taxes
The Company’s provision for income taxes is based upon estimated annual tax rates for the year applied to federal income as well as state and foreign income in various jurisdictions, permanent differences between book and tax items, tax credits and the Company’s change in relative income in each jurisdiction. The provision for income taxes and the effective tax rates for the periods presented were as follows:
| Three Months Ended March 31, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| Income before income taxes | $ | 157.0 | $ | 124.5 | |||||||||||||||||||
| Provision for income taxes | 37.1 | 29.1 | |||||||||||||||||||||
| Effective tax rate | 23.6 | % | 23.4 | % |
The effective tax rate for the three months ended March 31, 2026 and 2025 had no material discrete tax items impacting the effective tax rates.
Previous: Cover and table of contents · Next: Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations